NICE issues final positive guidance for GSK's Votrient
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given GlaxoSmithKline's targeted oral anticancer Votrient (pazopanib) the final green light for treating patients with advanced renal cell carcinoma (RCC) on the National Health Service.